On the evening of March 24th, FOREST CABIN (02657), a leading domestic high-end skincare company, released its annual performance report for 2025. The report indicates the company achieved annual operating revenue of 2.45 billion yuan, a year-on-year increase of 102.5%. Gross profit reached 2.009 billion yuan, up 101.4% compared to the previous year, while adjusted net profit was 401 million yuan, surging 100.1%. Multiple core operational metrics demonstrated high-quality growth, with continuously improving profitability, highlighting the company's enhanced resilience and operational efficiency within the high-end skincare sector.
This robust performance is underpinned by the synergistic development of the company's capabilities across product strength, brand power, and channel management. Continuous investment in raw material research has provided critical support for product innovation. By the end of 2025, a new cosmetic ingredient independently developed by FOREST CABIN, "Kluyveromyces Zhejiangensis/Camellia Chekiangoleosa Leaf Ferment Lysate Filtrate," officially passed the filing with the National Medical Products Administration. This marks the third new cosmetic ingredient derived from the Zhejiang Red Camellia to be successfully filed, following Camellia Chekiangoleosa Seed Oil and Candida Sphaerica/Camellia Chekiangoleosa Seed Oil Ferment, signifying ongoing advancement in combining modern biotechnology with local botanicals.
In March of this year, the company added two more Zhejiang Red Camellia ingredients to its portfolio, with "Camellia Chekiangoleosa Flower Extract" and "Camellia Chekiangoleosa Leaf Extract" both receiving approval. This solidifies the foundational research and development across the entire "flower, leaf, seed" chain and further enriches the company's raw material matrix. Currently, FOREST CABIN has successfully launched a PDRN ingredient sourced from camellia flowers. Related product series are expected to be launched successively between April and September 2026. Compared to traditional animal-derived PDRN, the Red Camellia PDRN demonstrates significant characteristics such as superior stability and sustainability, high safety with low irritation, smaller molecular weight for easier absorption, and excellent efficacy potential. It shows notable effectiveness in anti-wrinkle, brightening, repair, and anti-oxidation.
Furthermore, in 2025, FOREST CABIN hosted the second Scientific Research Conference on Cellular-Level Anti-Wrinkle Skincare and published the industry's first "Blue Paper on Cellular-Level Anti-Wrinkle Skincare in China." This document outlines solutions and technological directions for cellular-level anti-aging. Concurrently, the Cellular-Level Anti-Wrinkle Joint Research Laboratory, established in collaboration with Shanghai Jiao Tong University, and the Mitochondrial Anti-Wrinkle Research Platform were both launched within the year. These initiatives further strengthen fundamental research capabilities, facilitate the efficient translation of scientific findings into products, and lead the skincare industry into a new phase of precise anti-aging.
As of the end of 2025, FOREST CABIN held a cumulative total of 87 patents, 46 of which are invention patents, and employed 139 experienced R&D personnel. The team comprises experts from various fields including botany, biology, dermatology, and applied chemistry, with over 55% holding master's degrees or higher, ensuring the professionalism and foresight of R&D activities.
The continuous strengthening of scientific research capabilities has also enhanced the company's influence in shaping industry standards. In 2025, FOREST CABIN collaborated with relevant industry departments, associations, and leading enterprises to participate in formulating and releasing 12 group standards and 1 industry standard. The company was also deeply involved in drafting group standards related to the "skin nourishing with oils" niche segment, promoting its standardized development and further consolidating its leading position.
Looking ahead, FOREST CABIN stated that it will continue to focus on three strategic directions: high-end positioning, multi-brand development, and globalization. Centered around its core "1+4+N" hero products matrix, the company will leverage its raw material barriers and R&D advantages to deepen omni-channel synergy and brand value accumulation, thereby solidifying its leading position in the high-end domestic skincare market.
Comments